0A3M

BioNTech SE ADR

Stock London Stock Exchange – Stock Market Prices, News & Analysis

Entreprise spécialisée dans la recherche, le développement et la production de médicaments basés sur la technologie ARN messager, notamment pour les vaccins contre les maladies infectieuses et les traitements oncologiques.

£ 1.03

0.95 %

Healthcare & Biotech Healthcare & Biotech News Europe

BioNTech SE ADR

£ 1.03

0.95 %

0A3M

Biotechnologie Vaccins ARN messager Immunothérapie Oncologie Recherche pharmaceutique

Healthcare & Biotech Healthcare & Biotech News Europe

Price history of BioNTech SE ADR

Performance & Momentum

6 Months 8.03 %

1 Year 9.66 %

3 Years 21.65 %

5 Years 8.35 %

Momentum

Unlock this indicator

Strategic Analysis

BioNTech SE ADR • 2026

BioNTech SE positions itself as an innovative leader in biotechnology, leveraging messenger RNA technology to develop vaccines and oncology treatments. Its model is based on strong R&D capabilities and a growing portfolio in immunotherapy, targeting niche areas with high medical and commercial potential.

Strengths

Advanced expertise in mRNA technology, a breakthrough innovation in medicine.
Diversification of applications, notably in infectious disease vaccines and oncology treatments.
European positioning with global recognition that facilitates partnerships and market access.

Weaknesses

High volatility linked to the innovative nature of the business and the regulatory uncertainties of the biotech sector.
Significant dependence on a few key products, exposing the company to risks specific to those treatments.

Momentum

After several periods of decline, momentum remains moderate with a stabilized trend. This dynamic suggests cautious investor interest, with the market awaiting clear progress on new projects and clinical results to trigger a lasting rebound.

Ask our AI about BioNTech SE ADR

Analysis performed 1 month ago